We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.29B
AUM Growth
-$221M
Cap. Flow
-$280M
Cap. Flow %
-21.66%
Top 10 Hldgs %
58.27%
Holding
48
New
1
Increased
5
Reduced
14
Closed
7

Top Buys

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$18.6M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$5.52M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$4.97M
4
PCVX icon
Vaxcyte
PCVX
+$4.74M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.07M

Top Sells

Rank Stock Value
1
BN icon
Brookfield
BN
+$59.8M
2
CTLT
CATALENT, INC.
CTLT
+$54.7M
3
IRON icon
Disc Medicine
IRON
+$44.4M
4
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$30.7M
5
ASML icon
ASML
ASML
+$19.7M

Sector Composition

Rank Sector Weight
1 Healthcare 53.31%
2 Technology 28.76%
3 Industrials 8.35%
4 Communication Services 4.78%
5 Consumer Discretionary 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$562M
$18.1M 1.4%
1,000,000
+300,000
+43% +$5.52M
SPRB
27
Spruce Biosciences
SPRB
$129M
$14.5M 1.12%
89,631
– –
RLYB icon
28
Rallybio
RLYB
$85.8M
$12.4M 0.96%
273,500
-10,264
-4% -$503K
SILK
29
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10.8M 0.84%
333,884
+58,373
+21% +$2.13M
INSP icon
30
Inspire Medical Systems
INSP
$1.74B
$10.6M 0.82%
32,500
-27,500
-46% -$7.86M
CYT
31
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$9.52M 0.74%
3,662,636
-277,777
-7% -$582K
VERV
32
DELISTED
Verve Therapeutics
VERV
$9.38M 0.72%
500,000
-700,000
-58% -$11.7M
TMCI icon
33
Treace Medical Concepts
TMCI
$309M
$9.21M 0.71%
360,000
-180,000
-33% -$4.65M
ABCL icon
34
AbCellera Biologics
ABCL
$2.12B
$7.28M 0.56%
1,126,915
– –
GRTX
35
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$6.55M 0.51%
2,100,000
-359,021
-15% -$1.07M
IOBT
36
DELISTED
IO Biotech
IOBT
$6.41M 0.5%
3,277,932
– –
DMRA
37
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$6.29M 0.49%
99,912
– –
LVTX
38
DELISTED
LAVA Therapeutics
LVTX
$4.87M 0.38%
2,400,000
-670,558
-22% -$1.24M
KNTE
39
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.47M 0.19%
815,707
– –
MQ icon
40
Marqeta
MQ
$1.66B
$2.15M 0.17%
110,390
– –
SPRO icon
41
Spero Therapeutics
SPRO
$73M
$680K 0.05%
468,902
– –
KZR
42
DELISTED
Kezar Life Sciences
KZR
– –
-46,560
Closed -$1.46M
LUNG icon
43
Pulmonx
LUNG
$87.6M
– –
-510,555
Closed -$5.71M
NARI
44
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-180,000
Closed -$11.1M
CTLT
45
DELISTED
CATALENT, INC.
CTLT
– –
-832,878
Closed -$54.7M
DICE
46
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-536,100
Closed -$16.7M
VECT
47
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-3,610,461
Closed -$30.7M
BLU
48
DELISTED
BELLUS Health Inc.
BLU
– –
-2,137,975
Closed -$15.4M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q2 2023 Portfolio in Review

As of Q2 2023, Novo Holdings A/S held 48 positions worth $1.29B, down 15% from $1.52B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Novo Holdings A/S withdrew a net $280M in Q2 2023, closing 7 positions and reducing 14 holdings. Its most notable exit was CATALENT, INC., an estimated $54.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Novo Holdings A/S opened a new position in Cymabay Therapeutics worth $21.9M.

  • Novo Holdings A/S's largest Q2 2023 buy was Cymabay Therapeutics: 2,000,000 shares worth $21.9M.
  • Novo Holdings A/S added most to 4D Molecular Therapeutics in Q2 2023, an estimated $5.52M increase.
  • Novo Holdings A/S's biggest Q2 2023 reduction was Brookfield, cutting an estimated $59.8M.
  • Novo Holdings A/S fully exited CATALENT, INC. in Q2 2023, selling an estimated $54.7M.
  • Novo Holdings A/S's ten largest holdings make up 58% of its $1.29B portfolio in Q2 2023.
  • Novo Holdings A/S opened 1 new position and closed 7 in Q2 2023.
  • Novo Holdings A/S's portfolio value fell 15% quarter-over-quarter to $1.29B.

Based on Novo Holdings A/S's 13F filing for Q2 2023, filed 14 Aug 2023.